NervGen is a publicly traded (TSX-V: NGEN, OTCQX: NGENF) clinical stage biotech company dedicated to discovering and developing treatments for patients suffering from medical conditions related to nerve damage, either as a result of injury, neurodegenerative disease, or other causes.
In March 2016, Codi, the daughter-in-law of Dr. Harold Punnett, one of NervGen’s co-founders, fell and became a complete T-11 paraplegic. She has no sensation or function below the level of her belly button and the devastating injury changed the lives of Codi, and the rest of the family. In response to this terrible injury, Dr. Punnett began a personal quest to learn about spinal cord injury. Through his research he discovered a revolutionary nerve regeneration technology of deep biological logic in Dr. Jerry Silver’s work at Case Western Reserve University (CWRU). Dr. Silver and Dr. Punnett began a conversation that resulted in the formation of NervGen Pharma Corp. in 2018. Dr. Punnett’s hope is that the work performed by NervGen will be able to help Codi and others suffering from paralysis; he is also very excited that the technology may also lead to novel new treatments for other serious neurological conditions such as neurodegenerative diseases.
Key Facts About NervGen
- NervGen’s core technology targets a novel receptor called protein tyrosine phosphatase sigma (PTPσ).
- PTPσ is present in the central nervous system (CNS) and the peripheral nervous system (PNS). This receptor plays a key role when there is nerve damage where it impedes nerve regeneration, inhibits plasticity and inhibits remyelination.
- Inhibition of the PTPσ receptor has been shown to promote regeneration of damaged nerves, increase plasticity and stimulate remyelination in animal models. These effects have been accompanied by improvements of nerve and behavior function in animal models for various medical conditions.
- Our lead product is NVG-291, a specific and selective PTPσ inhibitor.
- We are planning to develop NVG-291 for multiple sclerosis, Alzheimer’s disease, and spinal cord injury.
- NVG-291 entered Phase 1 clinical trials in the first half of 2021.